

# Alpha Picks: Focusing On 2H26 Earnings

## Highlights

- Our portfolio's returns underperformed the market in Sep 26 (Our portfolio: -3.6% vs SET Index: -2.3%).
- The outperforming stocks were: a) BJC (+12.9%), b) BH (+0.8%), and c) BDMS (+2.0%). The underperforming stocks were: a) CPN (-8.6%), b) CPN (-6.1%), and c) CPALL (-8.1%).
- For Oct 26, the Thai equity market may face near-term challenges from high US Treasury yields, lower crude oil prices, and flooding risks. However, the medium- to long-term outlook remains positive, supported by positive EPS momentum, low financing costs, and negative real yields, which should attract capital into equities.
- Oct 26 Alpha Picks: BDMS, BH, BJC, CPN, ITC, KTC, PLANB, RATCH, THAI, TOP and TRUE.

## What's New

- Portfolio underperformed in Sep 26.** Our portfolio underperformed the market in Sep 26 (-3.6% vs SET Index: -2.3%). The outperforming stocks were: a) BJC (+12.9%), b) BH (+0.8%), and c) BDMS (-2.0%). The underperforming stocks were: a) MTC (-12.0%), b) CPN (-8.6%), and c) CPALL (-8.1%).
- Thai equities moved down in September.** The Thai equities market moved down in September, as the market was primarily pressured by the continued rise in US Treasury yields, which are likely to remain elevated for an extended period. This could trigger short-term capital rotation from equities into US Treasuries. In addition, concerns over flooding have increased, as the situation could weigh on economic conditions. The outperforming sectors were: a) petrochemical (+8.6%), b) electronics (+3.9%), and c) home improvement (+0.2%). The underperforming sectors were: a) finance (-7.8%), b) transportation (-5.2%), and c) property (-5.0%).
- More pressure in the short term.** The Thai equity market may face more challenges in October primarily due to: a) persistently high US Treasury yields, which could widen the US-Thai yield gap, trigger capital outflows, and weaken the baht; b) easing crude oil prices amid higher supply, potentially pressuring upstream energy stocks; and c) economic downside risks from flooding. However, the medium- to long-term outlook remains positive, supported by positive EPS momentum, low domestic financing costs, and negative real treasury yields, which should encourage capital inflows into equities.
- Focus on the companies that expect to have an impressive earnings outlook in 2H26.** We continue to recommend increasing exposure to stocks that are expected to see an impressive earnings outlook in 2H26.

## Action

- Oct 26 Alpha Picks:** BDMS, BH, BJC, CPN, ITC, KTC, PLANB, RATCH, THAI, TOP and TRUE
- Add PLANB,** as we are positive on PLANB's acquisition of a 46.28% stake in iCare Insurance from COM7, which should provide long-term returns from the growing mobile phone insurance and device protection businesses while diversifying income sources.
- Add TOP,** as we expect market GRM to remain strong in 2H26, supported by continued uncertainty surrounding the Middle East situation.
- Add TRUE,** to add a defensive stock during the market fluctuation while EV/EBITDA remains below that of ADVANC's.
- Drop CPALL, MTC, and SCC** due to a lack of catalysts.

## Analyst(s)

Kitpon Praipaisarnkit

kitpon@uobkh.co.th  
662 090 3352

Krit Tanarattananon

krit@uobkh.co.th

Thailand Research Team

research@uobkh.co.th

## Assistant Analyst(s)

Natthida Chuaysong

## Key Recommendations

| Company  | Rec | Share Price (Bt) | Target Price (Bt) |
|----------|-----|------------------|-------------------|
| BDMS TB  | BUY | 19.20            | 27.00             |
| BH TB    | BUY | 193.00           | 236.00            |
| BJC TB   | BUY | 17.50            | 21.00             |
| CPN TB   | BUY | 61.50            | 80.00             |
| ITC TB   | BUY | 16.30            | 22.00             |
| KTC TB   | BUY | 34.50            | 50.00             |
| PLANB TB | BUY | 6.95             | 6.80              |
| RATCH TB | BUY | 37.00            | 44.00             |
| THAI TB  | BUY | 5.70             | 6.80              |
| TOP TB   | BUY | 66.50            | 88.00             |
| TRUE TB  | BUY | 12.70            | 16.50             |

Source: Bloomberg

## Changes In Share Price

| Company   | Sep 26 (%) | To Date* (%) |
|-----------|------------|--------------|
| BDMS      | (2.0)      | 1.1          |
| BH        | 0.8        | 0.8          |
| BJC       | 12.9       | 8.0          |
| CPALL     | (8.1)      | (9.1)        |
| CPN       | (8.6)      | 6.5          |
| ITC       | (5.8)      | (6.9)        |
| KTC       | (7.4)      | 21.1         |
| MTC       | (12.0)     | (12.7)       |
| RATCH     | (3.9)      | (3.9)        |
| SCC       | (2.7)      | 5.8          |
| THAI      | (2.6)      | (14.9)       |
| Alpha     | (3.6)      |              |
| SET Index | (2.3)      |              |

\*Share price change since stock was selected as alpha pick

Source: Bloomberg, UOB Kay Hian

## Portfolio Returns

| (%)                       | 2025   | 1Q26 | 2Q26 | 3Q26  |
|---------------------------|--------|------|------|-------|
| SET return                | (10.0) | 15.0 | 9.9  | (2.0) |
| <b>Alpha Picks Return</b> |        |      |      |       |
| - Price-weighted          | (1.0)  | 24.9 | 2.9  | 2.1   |
| - Market cap-weighted     | (5.7)  | 16.8 | 2.6  | (1.5) |
| - Equal-weighted          | (1.6)  | 19.7 | 5.8  | (0.2) |

Source: Bloomberg

## Analysts' Top Alpha Picks

| Analyst                                           | Company | Rec | Performance | Catalyst                                                                      |
|---------------------------------------------------|---------|-----|-------------|-------------------------------------------------------------------------------|
| Benjaphol Suthwanich/<br>Nonpawit Vathanadachakul | BDMS    | BUY | 1.1         | Strong support from the influenza epidemic                                    |
| Benjaphol Suthwanich/<br>Nonpawit Vathanadachakul | BH      | BUY | 0.8         | Strong support from the influenza epidemic and return of Middle East patients |
| Tanapon Cholkadidamrongkul                        | BJC     | BUY | 8.0         | The MM Mega market acquisition, strong packaging earnings                     |
| Tanapon Cholkadidamrongkul                        | CPN     | BUY | 6.5         | New project launch                                                            |
| Nichapa Ratchabandit                              | ITC     | BUY | (6.9)       | Strong demand for pet food                                                    |
| Thanawat Thangchadakorn                           | KTC     | BUY | 21.1        | Government stimuli to strengthen domestic spending.                           |
| Nichapa Ratchabandit                              | PLANB   | BUY |             | The synergy deal with COM7.                                                   |
| Arsit Pamaranon                                   | RATCH   | BUY | (3.9)       | New PDP                                                                       |
| Benjaphol Suthwanich/<br>Nonpawit Vathanadachakul | THAI    | BUY | (14.9)      | Strong booking demand                                                         |
| Tanaporn Visaruthaphong/<br>Benjaphol Suthwanich  | TOP     | BUY |             | Market GRM remains high                                                       |
| Kitpon Praipaisarnkit/<br>Sirithat Prasertwuti    | TRUE    | BUY |             | Lower finance costs                                                           |
| Tanapon Cholkadidamrongkul                        | CPALL   | BUY | (9.1)       | Dropped                                                                       |
| Thanawat Thangchadakorn                           | MTC     | BUY | (12.7)      | Dropped                                                                       |
| Benjaphol Suthwanich                              | SCC     | BUY | 5.8         | Dropped                                                                       |

Source: UOB Kay Hian

## Sector Performance

| Sector           | Sep 26 (%)   | To Date* (%) |
|------------------|--------------|--------------|
| SETENERG         | (2.9)        | 31.8         |
| SETBANK          | (4.5)        | 25.6         |
| SETICT           | (3.6)        | 9.0          |
| SETETRON         | 3.9          | 53.3         |
| SETCOM           | (3.7)        | 8.1          |
| SETTRANS         | (5.2)        | 9.0          |
| SETFOOD          | (4.8)        | 6.5          |
| SETPROP          | (5.0)        | 15.3         |
| SETHLTH          | (1.2)        | 3.9          |
| SETFIN           | (7.8)        | 4.2          |
| SETCONMT         | (2.7)        | 29.4         |
| SETPREIT         | (0.9)        | 10.6         |
| SETPETRO         | 8.6          | 87.7         |
| SETINS           | (2.0)        | 15.7         |
| SETTOUR          | (3.0)        | (1.0)        |
| SETMEDIA         | (1.4)        | 16.5         |
| SETPKG           | (4.6)        | 50.8         |
| SETAGRI          | (2.0)        | 20.7         |
| SETCONS          | (1.3)        | 54.6         |
| SETPERS          | (3.2)        | 8.8          |
| SETAUTO          | (3.7)        | 7.4          |
| SETFASH          | (3.4)        | (5.2)        |
| SETSTEEL         | (5.4)        | 14.7         |
| SETPROF          | (3.0)        | (11.5)       |
| SETIMM           | (2.1)        | 36.0         |
| SETHOME          | 0.2          | (6.0)        |
| SETPAPER         | -            | 20.0         |
| <b>SET Index</b> | <b>(2.3)</b> | <b>23.8</b>  |

Source: Bloomberg, UOB Kay Hian

## BDMS – BUY (Benjaphol Suthwanish/Nonpawit Vathanadachakul)

- **Strong earnings outlook in 3Q26.** We started to see more promising signs of a 3Q26 outlook improvement in Jul 26. Thai patient revenue grew by a massive 9% yoy, while foreign patients' revenue rose 6% yoy. Total revenue jumped 8% yoy, making it the strongest month so far for Bangkok Dusit Medical Services (BDMS) in 2026. The key driver for the strong Thai patient growth is the epidemic, as we saw the number of influenza cases accelerate in Jul 26. For foreign patient revenue, the strongest contributors are Bangladeshi patients, whose numbers rebounded strongly after the visa bottleneck was resolved in late-2Q26. Revenue from Middle East patients also showed a mom recovery in Jul 26. We expect the high base from Cambodia patient revenue to normalise in 3Q26 as well. If we exclude Cambodia and Middle East patient revenue, foreign patient revenue in Jul 26 would have shown a strong growth of 14% yoy.
- **Gradual recovery path for Middle East patients.** Middle East patient revenue was -13% yoy in 1H26, with the sharpest decline recorded in Mar 26 following the onset of the conflict, which disrupted patient travel. Revenue began to recover in Apr 26, although it remained 36% below last year's level. In Jul 26, Middle East patient revenue was still 10% yoy below last year's, representing a meaningful improvement from the previous months. We expect Middle East patient revenue to return to normal levels in 3Q26, providing a meaningful boost to earnings. Meanwhile, foreign patient revenue rose 6% yoy in Jul 26, indicating an apparent recovery. The 3Q26 outlook should also benefit from continued patient engagement and pent-up demand from patients who were previously unable to travel.
- **Maintain BUY with a target price of Bt27.00.** Our valuation is based on a five-year average EV/EBITDA multiple of 16.0x. We started to see improving revenue from both Thai and foreign patients in Jul 26, particularly Middle East patients. Hence, we remain optimistic about a strong 2H26, on: a) the return

## Share Price Catalyst

- **Event:** Strong support from the surge in influenza cases.
- **Timeline:** 3Q26.

of Middle East patients, b) the epidemic during the rainy season in 3Q26, and c) the active promotions and packages that will boost revenue growth.

### BH – BUY (Benjaphol Suthwanish/Nonpawit Vathanadachakul)

- **Robust earnings outlook in 3Q26.** Management guided for around 3% yoy growth in 3Q26's top-line, as it is seeing a positive momentum in the return of Middle Eastern patients. However, we consider this conservative given that 2Q26 has already shown 4% yoy top-line growth despite the pressure from the Middle East war. We believe this guidance had been made based on a potential reignition of conflict in the Middle East. If there is no further escalation in the Middle East, we expect the growth of revenue to be stronger than guided. Management noted that strong momentum in Middle East patient arrivals continued into Jul-Aug 26, boding well for a robust 3Q26 earnings performance. Hence, we remain optimistic about Bumrungrad Hospital's (BH) outlook going forward.
- **New market opportunity from Iraq.** Management stated that BH now sees a new opportunity in the Iraq market and is currently waiting for the embassies to reestablish their connection for the first time in 20 years. In late-Jun 26, Iraq received approval to construct its embassy in Thailand once again. Depending on how fast the relationship is reestablished, BH can penetrate the Iraq market right away as it has already signed the guarantee of payment (GOP) agreement with the Iraqi government. The most sought-after treatments among the Iraqi are expected to be similar to other Middle Eastern countries, which have high demand for spine and orthopaedic surgeries, cardiovascular surgeries, oncologic treatments, and other neuroscience treatments.
- **Maintain BUY with a target price of Bt236.00.** Our valuation is based on 2026 EV/EBITDA multiple of 18.0x, which is around the five-year mean of its historical multiples. BH remains one of our top picks, due to: a) continuous strong flow Middle East patients in Jul-Aug 26; b) potential new markets like Iraq; and c) BH having already secured its medicine supply cost for 2026, which should help BH maintain its high margins.

### Share Price Catalyst

- **Event:** Strong support from the surge in influenza cases.
- **Timeline:** 3Q26.

### BJC – BUY (Tanapon Cholkadidamrongkul)

- **Our new 2027 earnings forecast is 13% above consensus.** We raise our 2027 core profit forecast by 7%, driven by three key factors: a) cost savings initiatives, as one-off expenses may be incurred in 2H26 but should generate significant savings from 2027 onwards, which we believe are not yet reflected in market perception; b) Big C recovery, with 3Q26 SSSG expected to turn positive for the first time since 1Q25; and c) stronger-than-expected MM Mega Market Vietnam (MMVN) performance.
- **Glass business: Best performance in the past decade.** BJC's glass factory is the largest glass production facility in Southeast Asia. After discussions with the glass business' management, we remain confident in its 2H26 outlook. Orders from both existing and new customers remain strong, supported by stronger demand and production disruptions at two key competitors. This has allowed BJC to gain market share across various product categories. We see BJC's strong customer relationships and cost leadership as key advantages in winning new orders. Meanwhile, its existing customer, Thai Beverage, continues to gain market share in both alcohol and non-alcohol beverages, supporting demand. As a result, the factory continues to operate at full capacity, similar to 2Q26. We expect glass gross margin to expand yoy in 3Q26, driven by operating leverage and lower raw material costs, which should more than offset higher natural gas costs.

### Share Price Catalyst

- **Event:** The MMVN acquisition, strong packaging earnings.
- **Timeline:** 2026.

Overall, we expect the glass business to remain a key earnings driver throughout 2H26.

- **Maintain BUY and raise target price to Bt21.00 (from Bt18.00).** We roll over our target price to a 2027F PE of 15x, equivalent to -2SD to BJC's and -1.5SD to peers' five-year averages. BJC trades at 15x PE, in line with peers, but offers stronger earnings momentum.

### CPN – BUY (Tanapon Cholkadidamrongkul)

- **Promising outlook for 2H26.** Earnings should be supported by the ramp-up of newly opened assets and continued growth from existing malls. Key catalysts include the ongoing ramp-up of Central Park and Central Krabi, as well as the upcoming openings of Central Northville and new hotel projects. We are confident that management's target of 5-8% yoy growth in rental and service income in 2026 is achievable, while occupancy should remain at healthy levels. We also expect operating leverage from mature assets to partly offset the initial margin dilution from new projects. Overall, strong 2Q26 rental performance, healthy occupancy and an expanding asset base should support continued earnings growth in 2H26.
- **Results recap.** Central Pattana (CPN) reported 2Q26 net profit of Bt4.75b (+10% yoy, -4% qoq) and core profit of Bt4.65b (+19% yoy, -5% qoq). The solid earnings growth was driven by strong operating performance across all business segments, with total revenue rising 8% yoy to Bt13.1b. Gross margin remained healthy at around 59.3%, while SG&A-to-revenue was broadly stable yoy. Interest expense declined yoy, supported by lower borrowing costs, while equity income also increased yoy, providing additional support to core profit. On a 1H26 basis, core profit reached around Bt9.6b, accounting for approximately 50% of our full-year forecast.
- **Maintain BUY with a target price of Bt80.00.** We use SOTP methodology, valuing CPN's core business at Bt79.8/share based on DCF, with a WACC of 7.0% and terminal growth of 1.5%. The residential business is valued at Bt0.2/share based on 5x 2026F PE. Our target price implies a 2026F PE of 18x and EV/EBITDA of 11x. We maintain an optimistic outlook on CPN, underpinned by its long-term strategic expansion and growing asset base.

### Share Price Catalyst

- **Event:** CenTRal cENtrAL rental business to boost 2028's earnings by 1.5%.
- **Timeline:** 2028.

### ITC – BUY (Nichapa Ratchabandit)

- **Expect core earnings to rise qoq and yoy.** We expect i-Tail Corporation's (ITC) net profit to be at Bt790m, (-3% yoy and -6% qoq). Excluding one-off items, we foresee 3Q26 core profit at Bt805m (+2.3% yoy, but -6% qoq). However, adjusting for the tariff refund recognised in 2Q26, core profit would grow 2.3% yoy and 11% qoq.
- **Pet food sales momentum remains strong.** ITC's top-line is expected to increase to Bt5.4b in 3Q26 (+14% yoy, +19% qoq), driven mainly by higher sales volume in the US market. The premium segment is likely to remain strong, accounting for more than 52.4% of sales.
- **Maintain BUY with a higher target price of Bt22.00 (previously Bt20.50).** We roll over our valuation base to 2027 EPS. We peg its PE target to its three-year mean, at 17x.
- **We reiterate our positive view on ITC,** supported by the strong sales growth momentum in the pet food industry, which we expect to deliver double-digit yoy growth in 2H26, particularly driven by the premium segment. In addition, ITC's initial pricing adjustments in 3Q26 should help support margin resilience. We forecast 2027 earnings at Bt3.9b (+13.5% yoy).

### Share Price Catalyst

- **Event:** Strong demand for pet food.
- **Timeline:** 2026.

**KTC – BUY (Thanawat Thangchadakorn)**

- **2Q26 results beat.** Krungthai Card (KTC) posted a 2Q26 net profit of Bt2.23b, up 17% yoy and 3% qoq. The results beat our and consensus estimates by 11% and 6% respectively. Excluding provisioning, the company's pre-provision operating profit rose 3% yoy and was flat qoq.
- **KTC to prioritise maintaining good asset quality.** Due to the economic uncertainty and low growth, driven by high household debt and rising living costs, KTC cautiously grew its loan portfolio in 2Q26. Meanwhile, KTC planned a strategic decline in lease receivables, resulting in a continuous shrinkage in its loan portfolio and a reduction in NPL in 2Q26. To navigate this challenging environment, KTC prioritises a prudent expansion strategy focused on portfolio quality and risk management. This defensive approach aims to mitigate economic volatility while securing sustainable, long-term growth. We are optimistic about KTC's asset quality outlook.
- **Maintain BUY with a higher target price of Bt50.00 (previously Bt44.00),** based on the Gordon Growth Model (cost of equity: 11.5%, long-term growth: 3%). This implies 2.7x 2026F P/B, which is -0.5SD to its historical five-year mean.

**Share Price Catalyst**

- **Event:** Government stimulus to strengthen domestic spending.
- **Timeline:** 2026.

**PLANB – BUY (Nichapa Ratchabandit)**

- **Earnings beat.** Plan B Media (PLANB) reported a 2Q26 net profit of Bt297m (+10% yoy, +43% qoq). Results exceeded our forecast and the market consensus by 6% and 4%, respectively, mainly driven by a higher-than-expected gross profit margin.
- **Profitability expanded on stronger business mix.** Gross profit margin expanded to 33.5% in 2Q26 from 32.5% in 2Q25 and 31.3% in 1Q26, supported by stronger contributions from the out-of-home media and sports marketing businesses. SG&A-to-sales rose to 14.2% in 2Q26 from 12.9% in 2Q25 and 14.0% in 1Q26, mainly due to higher selling expenses, particularly commission expenses.
- **Maintain BUY with a target price of Bt6.80.** Our target price is based on the DCF methodology and corresponds to 22x 2027F PE (equivalent to PLANB's five-year average PE at -1SD).
- **We remain positive on PLANB's outlook,** as we believe it will continue to be the most resilient player in the media sector, supported by: a) its leading position in the OOH media market, particularly in prime locations; b) strong revenue growth from its engagement marketing segment, driven by its boxing business, which carries higher profitability than the overall business; and c) potential media capacity expansion following the investment in COM7, which could provide upside risk to earnings.

**Share Price Catalyst**

- **Event:** Improvement in utilisation rate, expansion in media capacity, economic growth, the synergy deal with COM7.
- **Timeline:** 2027.

**RATCH – BUY (Arsit Pamaranont)**

- **Earnings expected to improve in 2H26.** While 2Q26 earnings came in below our expectation, we see the shortfall largely as a timing issue and maintain our 2026F earnings forecast of Bt7.0b. We expect a stronger earnings recovery in 2H26, supported by the normalisation of Hongsa Power Company (HPC) and Paiton following maintenance, together with potential improvement at Hin Kong Power (HKP) from a relatively low availability factor in 2Q26.
- **New PDP 2026 is the key driver.** We believe Thailand may need to open Independent Power Producer (IPP) bidding as existing reserve margins could be consumed faster than expected by rising data centre demand and several existing IPPs are gradually approaching Power Purchasing

**Share Price Catalyst**

- **Event:** New PDP.
- **Timeline:** 2026.

Agreement (PPA) expiry. In addition, the country will likely require more firm power and flexible gas-fired generation to support higher renewable penetration under the new Power Development Plan (PDP).

- **Maintain BUY with a rolled-over target price to 2027 at Bt44.00 (previously Bt35.00)**, reflecting our earnings upgrades for 2027-28 and higher strategic value assigned to RATCH's existing power infrastructure. We believe the market should price in potential value creation from the Ratchaburi Group (RG) site, supported by potential PPA extension and potential from data center power demand. Despite the recent share price rally, we see further upside from improving earnings visibility and RATCH's transition from a defensive dividend play toward a growth-oriented company.

### THAI – BUY (Benjaphol Suthwanish/Nonpawit Vathanadachakul)

- **Positive tone from analyst meeting.** We attended Thai Airways' (THAI) analyst meeting to review its 2Q26 results and the tone was positive.
- **Strong bookings in 3Q26.** THAI is starting to see stronger flight demand in 3Q26 and will not be reducing flights like in 2Q26. The cabin factor in Europe routes is now very strong at over 80% based on Jul-Aug 26 bookings, which is a strong improvement from 2Q26's cabin factor at 70% for Europe routes. The bookings in 3Q26 currently are already up yoy, which is an improvement from our previous update. Even the seasonally weakest month of Sep 26 has shown bookings growth yoy which reflects strong travel demand. This has shown THAI's ability to improve its weaker areas in 2Q26, such as the Europe route. The passenger yield in 3Q26 should decline slightly qoq from the decrease in ticket price but should remain at a higher level than during the pre-war period.
- **Bookings in 2H26 still have room for fuel surcharge.** Up to now, THAI has sold up to around 30% of total tickets in 4Q26. This gives THAI flexibility to cope with the possibility of increased jet fuel prices, as the situation in the Middle East has not concluded. The remaining 70% of tickets are still eligible for a price increase due to the fuel surcharge. If fuel prices exceed US\$150 per barrel, we could see THAI increase its ticket price again. This wiggle room provides THAI with good protection from possible downsides due to fuel prices.
- **Maintain BUY with a target price of Bt6.80.** Our valuation for THAI is rolled over to 2027, based on a PE multiple of 8.0x (based on 2SD below the 2017-19 historical mean multiple). We believe that THAI's valuation remains undemanding while the overhang over the lock-up period expiry has already been resolved. The 3Q26 outlook is gradually improving as the booking demand gets stronger, and margins should also improve qoq.

### Share Price Catalyst

- **Event:** Strong booking demand.
- **Timeline:** 3Q26.

### TOP – BUY (Tanaporn Visaruthaphong/Benjaphol Suthwanish)

- Thai Oil (TOP) and Global Power Synergy (GPSC) have announced to the Stock Exchange of Thailand (SET) that the construction work and certain conditions precedent under the Asset Purchase Agreement for GPSC's acquisition of TOP's energy recovery unit (ERU) project could not be completed by the Long Stop Date of 31 Aug 26. As a result, the transfer of ownership of the ERU project could not proceed as originally planned. Both parties remain in discussions with a conclusion expected by 30 Oct 26 or such other date as may be mutually agreed upon by both parties.
- We raise TOP's core earnings estimates following an upward revision to our market GRM assumptions for 2026-27. We expect market GRM to remain strong in 2H26, supported by continued uncertainty surrounding the Middle East situation, with elevated refining margins likely to persist into early-27. Accordingly, we raise our market GRM assumptions for TOP to

### Share Price Catalyst

- **Event:** Market GRM remains high.
- **Timeline:** 2026.

US\$18.00/bbl in 2026 (from US\$12.50/bbl) and US\$9.50/bbl in 2027 (from US\$8.00/bbl). As a result, we increase our 2026 core earnings estimate by 41% to Bt50.5b (from Bt35.92b) and our 2027 estimate by 38% to Bt24.71b (from Bt17.85b).

- **Upgrade TOP to BUY (previously HOLD)**, with a higher 2027 target price of Bt88.00 (previously Bt64.00). The upgrade reflects our revised 2026-27 core earnings estimates. We maintain our 8.0x 2027E PE valuation methodology, in line with the regional refinery sector's core forward PE multiple.

## TRUE – BUY (Kitpon Praipaisarnkit /Sirithat Prasertwuti)

- **Earnings should remain healthy, reaching an all-time high since the amalgamation.** We expect True Corporation (TRUE) to report a net profit of Bt6.97b (+343% yoy, +6% qoq), marking an all-time high since the amalgamation. Earnings are projected to remain healthy, supported by continued growth across several key businesses and lower finance costs qoq. Sales could come in at Bt46.54b (-1% yoy, +1% qoq). However, we expect core service revenue to continue growing both yoy and qoq to Bt41.8b (+1.3% yoy, +1.0% qoq), driven by healthy performance in mobile, broadband, and TV, despite 3Q26 normally being a soft season, particularly for handset sales, as iPhone sales are likely to contribute mainly in 4Q26.
- **We maintain BUY with a target price of Bt16.50 (from Bt15.70).** Our target price is based on a DDM, assuming a cost of equity of 8.5%, a risk-free rate of 2.3%, and an equity risk premium of 6.4%, which lies between our base-case and bull-case assumptions, together with an 85-90% dividend payout ratio. Our valuation also implies 7.8x EV/EBITDA, or around +1.0SD above TRUE's two-year mean.

## Share Price Catalyst

- **Event:** Lower finance costs.
- **Timeline:** 4Q26.

## Valuation Of Analysts' Alpha Picks

| Company                        | Ticker   | Rec | Price     | Target | Upside | Last  | PE   |       |       | Yield | ROE   | Market | Price/ |
|--------------------------------|----------|-----|-----------|--------|--------|-------|------|-------|-------|-------|-------|--------|--------|
|                                |          |     | 30 Sep 26 | Price  | To TP  | Year  | 2025 | 2026F | 2027F | 2026F | 2026F | Cap.   | NAV ps |
|                                |          |     | (Bt)      | (Bt)   | (%)    | End   | (x)  | (x)   | (x)   | (%)   | (%)   | (Bt)   | (x)    |
| Bangkok Dusit Medical Services | BDMS TB  | BUY | 19.20     | 27.00  | 40.63  | 12/25 | 19.3 | 18.7  | 17.4  | 4.0   | 14.5  | 9,136  | 2.8    |
| Bumrungrad Hospital            | BH TB    | BUY | 193.00    | 236.00 | 22.28  | 12/25 | 22.3 | 21.9  | 20.4  | 2.5   | 24.9  | 4,594  | 5.2    |
| Berli Jucker                   | BJC TB   | BUY | 17.50     | 21.00  | 20.00  | 12/25 | 17.5 | 11.3  | 12.9  | 4.5   | 4.8   | 2,100  | 0.6    |
| Central Pattana                | CPN TB   | BUY | 61.50     | 80.00  | 30.08  | 12/25 | 14.6 | 14.1  | 13.1  | 4.1   | 15.8  | 8,264  | 2.3    |
| I-Tail Corporation             | ITC TB   | BUY | 16.30     | 22.00  | 34.97  | 12/25 | 16.4 | 14.2  | 12.5  | 6.3   | 14.2  | 1,464  | 2.3    |
| Krungthai Card                 | KTC TB   | BUY | 34.50     | 50.00  | 44.93  | 12/25 | 11.4 | 10.3  | 9.8   | 5.6   | 18.7  | 2,663  | 1.8    |
| Plan B Media                   | PLANB TB | BUY | 6.95      | 6.80   | (2.16) | 12/25 | 28.9 | 26.7  | 23.2  | 2.2   | 9.4   | 957    | 2.7    |
| Ratch Group                    | RATCH TB | BUY | 37.00     | 44.00  | 18.92  | 12/25 | 12.9 | 11.4  | 11.4  | 4.5   | 6.8   | 2,409  | 0.9    |
| Thai Airways International     | THAI TB  | BUY | 5.70      | 6.80   | 19.30  | 12/25 | 5.2  | 8.6   | 6.7   | 2.9   | 22.8  | 4,830  | 1.8    |
| Thai Oil                       | TOP TB   | BUY | 66.50     | 88.00  | 32.33  | 12/25 | 10.2 | 2.8   | 6.0   | 5.3   | 26.7  | 4,448  | 0.7    |
| True Corporation               | TRUE TB  | BUY | 12.70     | 16.50  | 29.92  | 12/25 | 47.5 | 15.9  | 14.6  | 2.4   | 34.9  | 13,138 | 5.2    |

Source: Bloomberg, UOB Kay Hian

**IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS**

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."